+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Fibromyalgia (Fibromyalgia Syndrome) - Pipeline Review, H1 2020

  • ID: 4911689
  • Drug Pipelines
  • January 2020
  • Region: Global
  • 115 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Aptinyx Inc
  • Astellas Pharma Inc
  • Cytocom Inc
  • FSD Pharma Inc
  • H. Lundbeck AS
  • Intec Pharma Ltd
  • MORE
Fibromyalgia (Fibromyalgia Syndrome) - Pipeline Review, H1 2020

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Fibromyalgia - Pipeline Review, H1 2020, provides an overview of the Fibromyalgia (Central Nervous System) pipeline landscape.

Fibromyalgia is a disorder characterized by widespread musculoskeletal pain accompanied by fatigue, sleep, memory and mood issues. Symptoms include fatigue, depression, headaches, and pain or cramping in the lower abdomen. The predisposing factors include family history, rheumatoid arthritis or lupus. Treatment includes pain relievers, antidepressants and anti-seizure drugs.

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Fibromyalgia - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Fibromyalgia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Fibromyalgia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Fibromyalgia (Fibromyalgia Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 5, 4, 1, 6 and 1 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively.

Fibromyalgia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from a proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Fibromyalgia (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Fibromyalgia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Fibromyalgia (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Fibromyalgia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Fibromyalgia (Central Nervous System)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Fibromyalgia (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Fibromyalgia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Aptinyx Inc
  • Astellas Pharma Inc
  • Cytocom Inc
  • FSD Pharma Inc
  • H. Lundbeck AS
  • Intec Pharma Ltd
  • MORE
  • Introduction
  • Fibromyalgia (Fibromyalgia Syndrome) - Overview
  • Fibromyalgia (Fibromyalgia Syndrome) - Therapeutics Development
  • Fibromyalgia (Fibromyalgia Syndrome) - Therapeutics Assessment
  • Fibromyalgia (Fibromyalgia Syndrome) - Companies Involved in Therapeutics Development
  • Fibromyalgia (Fibromyalgia Syndrome) - Drug Profiles
  • Fibromyalgia (Fibromyalgia Syndrome) - Dormant Projects
  • Fibromyalgia (Fibromyalgia Syndrome) - Discontinued Products
  • Fibromyalgia (Fibromyalgia Syndrome) - Product Development Milestones
  • Appendix
List of Tables
  • Number of Products under Development for Fibromyalgia (Fibromyalgia Syndrome), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Aptinyx Inc, H1 2020
  • Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Astellas Pharma Inc, H1 2020
  • Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Cytocom Inc, H1 2020
  • Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by FSD Pharma Inc, H1 2020
  • Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by H. Lundbeck AS, H1 2020
  • Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Innovative Med Concepts LLC, H1 2020
  • Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Intec Pharma Ltd, H1 2020
  • Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2020
  • Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Luye Pharma Group Ltd, H1 2020
  • Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by NeuroCycle Therapeutics Inc, H1 2020
  • Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by One World Cannabis Ltd, H1 2020
  • Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by PRISM Pharma Co Ltd, H1 2020
  • Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Tetra Bio-Pharma Inc, H1 2020
  • Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Teva Pharmaceutical Industries Ltd, H1 2020
  • Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Tonix Pharmaceuticals Holding Corp, H1 2020
  • Fibromyalgia (Fibromyalgia Syndrome) - Pipeline by Vitality Biopharma Inc, H1 2020
  • Fibromyalgia (Fibromyalgia Syndrome) - Dormant Projects, H1 2020
  • Fibromyalgia (Fibromyalgia Syndrome) - Dormant Projects, H1 2020 (Contd..1), H1 2020
  • Fibromyalgia (Fibromyalgia Syndrome) - Dormant Projects, H1 2020 (Contd..2), H1 2020
  • Fibromyalgia (Fibromyalgia Syndrome) - Discontinued Products, H1 2020
List of Figures
  • Number of Products under Development for Fibromyalgia (Fibromyalgia Syndrome), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Aptinyx Inc
  • Astellas Pharma Inc
  • Cytocom Inc
  • FSD Pharma Inc
  • H. Lundbeck AS
  • Innovative Med Concepts LLC
  • Intec Pharma Ltd
  • Jiangsu Hengrui Medicine Co Ltd
  • Luye Pharma Group Ltd
  • NeuroCycle Therapeutics Inc
  • One World Cannabis Ltd
  • PRISM Pharma Co Ltd
  • Tetra Bio-Pharma Inc
  • Teva Pharmaceutical Industries Ltd
  • Tonix Pharmaceuticals Holding Corp
  • Vitality Biopharma Inc
Note: Product cover images may vary from those shown
Adroll
adroll